ArticleAIDS research and therapy2026
Brief communication: virological response and drug resistance patterns among men who have sex with men in Yaoundé-Cameroon.
Article in AIDS research and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Men having sex with men (MSM) in Cameroon are disproportionately affected by HIV. We evaluated virological response and HIV drug resistance (HIVDR) at a community-based organization between 2022 and 2023. Enhanced adherence counselling (EAC) sessions were conducted for all and cases with unsuppressed viral load (VL > 1000 copies/ml) underwent genotyping. From 502 treatment-experienced MSM enrolled, 95 (18.9%) had unsuppressed VL with 82 (86.3%) accepting to participate (ART-duration: 3 [2-5] years; 95.1% (78/82) under Tenofovir + Lamivudine + Dolutegravir). EAC led to 97.6% (80/82) suppression with 1/2 participant harboring HIVDR. High suppression rates and low HIVDR demonstrate the effectiveness of treatment strategies locally; supporting the possibility of global HIV elimination targets among key populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.